Qiuyun Luo*†1, Wentao Pan*†‡1, Suna Zhou*†1,
Guangfeng Wang‡, Hanjie Yi*§, Lin Zhang*¶,
Xianglei Yan*†, Luping Yuan*†, Zhenyi Liu#, Jing Wang**, Haibo Chen#, MiaoZhen Qiu*††,
DaJun Yang*†‡, Jian Sun*‡‡
Oncology Research, Vol.28, No.4, pp. 331-344, 2020, DOI:10.3727/096504020X15825405463920
Abstract Despite therapeutic advances, the effective treatment for relapsed or refractory diffuse large B-cell lymphoma
(DLBCL) remains a major clinical challenge. Evasion of apoptosis through upregulating antiapoptotic B-cell
lymphoma-2 (BCL-2) family members and p53 inactivation, and abnormal activation of B-cell receptor signaling pathway are two important pathogenic factors for DLBCL. In this study, our aim is to explore a rational
combination of BCL-2 inhibitor plus Bruton’s tyrosine kinase (BTK) blockade or p53 activation for treating
DLBCL with the above characteristics. We demonstrated that a novel BCL-2 selective inhibitor APG-2575
effectively suppressed DLBCL with BCL-2 high expression… More >
Login
Register
